Clinical Trial Update: A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 multicenter, open-label study of the EGFR-mutant TKI EGF816 in adult patients with EGFR-mutant solid malignancies, including advanced non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGF816

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-10-26